These two diagnostics stocks are down 40-60% this year but brokerages sees more downside

Dr. Lal Pathlabs and Metropolis Healthcare: The listed diagnostic players are facing intense competition from the new entrants. Aggressive pricing and new bundled offering will lower margins and lower realization per patient for large incumbent chains.

Diagnostics sector may see a de-rating, sell Dr. Lal PathLabs, Metropolis Healthcare, says Antique Broking

<ul><li>Antique said a closer look at diagnostics companies suggests that growth per patient realization is going to remain under pressure for a considerable future.</li></ul>

Business

Economy

Global Markets

India

Local Markets

Main

Latest

Top News

Markets

Personal  Finance

Deep Dive

Investing Mantras

Top Dr. Lal Pathlabs News

markets

These two diagnostics stocks are down 40-60% this year but brokerages sees more downside

markets

Diagnostics sector may see a de-rating, sell Dr. Lal PathLabs, Metropolis Healthcare, says Antique Broking